作者: Gregory Barshtein , Leonid Livshits , Leonid D. Shvartsman , Noa Ofek Shlomai , Saul Yedgar
DOI: 10.1007/S12013-015-0705-6
关键词:
摘要: Nanoparticles (NPs) are drawing an increasing clinical interest because of their potential use as drug carriers. Recently, a new strategy for elevation of NPs in vivo circulation time has been proposed, specifically, utilizing red blood cells (RBCs) as a carrier for NPs, that are loaded with a drug, by interaction (in vitro) of human RBCs with NPs (RBC NP). This class of delivery set-up, combines advantages of natural RBCs and synthetic biomaterials. Previous studies demonstrated that NPs initiated hemolysis of RBC and activated cells aggregation …